Burbank-based genetic testing firm Endocanna Well being Inc. has acquired a United States patent for its DNA take a look at that analyzes a person’s cannabinoid neuron system to find out whether or not any hashish merchandise could trigger adverse impacts.
In response to Endocanna Well being, the patent award, which it introduced this month, is outwardly the primary patent for DNA testing associated to hashish merchandise.
The take a look at is designed to assist customers keep away from hostile well being impacts from hashish merchandise. Since hashish merchandise have gained authorized standing in a number of states over the previous 20 years – first for medical makes use of after which for broader and leisure makes use of – the variety of emergency room visits has skyrocketed from folks struggling extreme reactions to hashish.
For instance, in accordance with Endocanna Well being, the variety of emergency room visits by hashish customers over 65 years of age in California jumped practically twentyfold between 2005 and 2019.
This development has gained nationwide consideration. ABC Information’ “Nightline” earlier this month featured a section on cannabinoid hyperemesis syndrome, or CHS, a uncommon situation introduced on by excessive hashish consumption charges that leads to extreme vomiting episodes that in just a few situations have confirmed deadly.
The information section identified that whereas the leap within the variety of emergency room visits coincided with the unfold of marijuana legalization, the leap might also be as a consequence of growing efficiency ranges of the marijuana merchandise consumed.
Endocanna Well being’s DNA take a look at is designed to flag people who could be at increased danger of CHS or different hostile reactions to hashish merchandise. Endocanna then applies a man-made intelligence platform to suggest exact cannabinoid ratios and terpene mixtures (which yield particular moods, akin to rest or an uplifting impact) in addition to merchandise that match these profiles.
Endocanna’s genetic take a look at platform is aimed toward each hashish customers and their prescribing physicians.
“We’re proud to supply a personalised platform that successfully addresses critical well being issues whereas eradicating the related danger of hostile reactions,” mentioned Len Could, Endocanna’s chief govt.
With this evaluation in hand, Endocanna can provide the advisable hashish product formulations and dosage allotments to every of its clients.
“We all know that everybody responds to hashish merchandise in a different way,” Could continued. “That’s why personalised cannabinoid therapeutics are important to making sure higher well being outcomes. We’re thrilled to obtain the mental property safety for our complete DNA take a look at that’s pioneering endocannabinoid compatibility.”
Could, who has researched cannabinoids and their impression on human physiology for greater than twenty years, launched Endocanna Well being in 2017. In response to an interview in Authority Journal posted on Endocanna’s web site, Could mentioned he determined to begin the corporate after observing that teams of individuals utilizing hashish to deal with the identical medical situation would have totally different reactions to the identical hashish product.
Endocanna Well being mentioned within the patent announcement that it has two different patents pending for its proprietary cannabinoid formulations and its synthetic intelligence platform.